Table 2.
Logistic regression analyses of associations between epidermal growth factor promoter polymorphisms and risk of gastric cancer
| Genotype | Cases (n = 617) | Controls (n = 660) | Crude OR (95% CI) | Adjusted OR † (95% CI) | ||
|---|---|---|---|---|---|---|
| n | % | n | % | |||
| EGF G61A | ||||||
| GG | 333 | 54.0 | 314 | 47.6 | 1.00 | 1.00 |
| GA | 242 | 39.2 | 289 | 43.8 | 0.79 (0.63–0.99) | 0.78 (0.62–0.99) |
| AA | 42 | 6.8 | 57 | 8.6 | 0.70 (0.45–1.07) | 0.68 (0.44–1.05) |
| GA/AA | 284 | 46.0 | 346 | 52.4 | 0.77 (0.62–0.96) | 0.77 (0.61–0.95) |
| A allele | 326 | 26.4 | 403 | 30.5 | ||
| EGF G‐1380A | ||||||
| GG | 451 | 73.1 | 462 | 70.0 | 1.00 | 1.00 |
| GA | 143 | 23.2 | 173 | 26.2 | 0.85 (0.66–1.10) | 0.83 (0.64–1.08) |
| AA | 23 | 3.7 | 25 | 3.8 | 0.94 (0.53–1.69) | 0.95 (0.53–1.70) |
| GA/AA | 166 | 26.9 | 198 | 30.0 | 0.86 (0.67–1.10) | 0.85 (0.66–1.08) |
| A allele | 189 | 15.3 | 223 | 16.9 | ||
| EGF A‐1744G | ||||||
| AA | 408 | 66.1 | 403 | 61.1 | 1.00 | 1.00 |
| AG | 181 | 29.3 | 234 | 35.5 | 0.76 (0.60–0.97) | 0.77 (0.61–0.98) |
| GG | 28 | 4.5 | 23 | 3.5 | 1.20 (0.68–2.12) | 1.25 (0.71–2.22) |
| AG/GG | 209 | 33.9 | 257 | 38.9 | 0.80 (0.64–1.01) | 0.81 (0.65–1.02) |
| G allele | 237 | 19.2 | 280 | 21.2 | ||
| Combined analysis ‡ | ||||||
| No variant locus | 117 | 19.0 | 74 | 11.2 | 1.00 | 1.00 |
| One variant locus | 343 | 55.6 | 373 | 56.5 | 0.58 (0.42–0.81) | 0.58 (0.42–0.80) |
| Two to three variant loci | 157 | 25.5 | 213 | 32.3 | 0.47 (0.33–0.67) | 0.46 (0.32–0.66) |
†
Adjusted for age, sex, smoking status and drinking status.
‡
Assuming dominant genetic model in each locus, that is, heterozygote and variant homozygote versus wild type homozygote. CI, confidence interval; EGF, epidermal growth factor gene; OR, odds ratio.